[多发性骨髓瘤交替治疗的结果——细胞抑制剂VBMCP与重组干扰素α-2B]
[Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
作者信息
Gola A, Usnarska-Zubkiewicz L, Wołowiec D, Urbaniak-Kujda D, Kotlarek-Haus S
机构信息
Klinika Hematologii i Chorób Rozrostowych AM, Wrocławiu.
出版信息
Pol Arch Med Wewn. 1993 Aug;90(2):134-41.
In 19 patients with recently diagnosed multiple myeloma 3-week cycles of vincristine, BCNU, melphalan, cyclophosphamide and prednisone alternating with interferon were administered over 6-12 months. Results were compared with a control group of 33 myeloma patients treated exclusively with VBMCP cytostatics. In interferon treated patients objective response was more frequent (76%) and median survival time longer (above 35 months).
对19例近期诊断为多发性骨髓瘤的患者，在6至12个月内给予长春新碱、卡莫司汀、美法仑、环磷酰胺和泼尼松3周疗程，并与干扰素交替使用。将结果与33例仅接受VBMCP细胞抑制剂治疗的骨髓瘤患者对照组进行比较。在接受干扰素治疗的患者中，客观缓解更为常见（76%），中位生存时间更长（超过35个月）。
Zotero 插件